Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease
Abstract Background Alzheimer's disease (AD) is a neurodegenerative disorder and the predominant type of dementia worldwide. It is characterized by the progressive and irreversible decline of cognitive functions. In addition to the pathological beta-amyloid (Aβ) deposition, glial activation, an...
Main Authors: | Min Zhang, Zhan Zhang, Honghong Li, Yuting Xia, Mengdan Xing, Chuan Xiao, Wenbao Cai, Lulu Bu, Yi Li, Tae-Eun Park, Yamei Tang, Xiaojing Ye, Wei-Jye Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Translational Neurodegeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40035-023-00388-4 |
Similar Items
-
Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema
by: Sever Ozkan, et al.
Published: (2019-01-01) -
The influence of bevacizumab on platelet function
by: M Fehr, et al.
Published: (2011-07-01) -
Bevacizumab for Glioblastoma—A Promising Drug or Not?
by: Ryo Nishikawa, et al.
Published: (2013-11-01) -
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01) -
Cerebrovascular ultrasound in stroke prevention and treatment /
by: Alexandrov, Andrei V.
Published: (2004)